Evaxion A/S EVAX
2.78 USD +0.01 (+0.36%)
Regular-session close
2.81 +0.03 +0.94%
After hours · Nov 17, 7:16 PM ET
2.70 Day range 2.82
2.65 52-week range 6.92
- YTD
- -41.72%
- 1 year
- -46.64%
News
globenewswire.com Evaxion announce 2027 financial calendar COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…benzinga.com Evaxion A/S Submits Amendment To Its Registration Statement On Form F-1 Regarding 2025 Debt Settlement Agreement With The European Investment Bank With SEC Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its registration…
globenewswire.com Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has…benzinga.com Evaxion Announces Data From Its Phase 2 Study Of EVX- In Participants With Advanced Melanoma Demonstrates Induced Immune Responses, Underlines Predictive Performance Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2…
globenewswire.com New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
defenseworld.net Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Evaxion A/S (NASDAQ:EVAX) Financial Analysis Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…benzinga.com Evaxion To Demonstrate New Data For EVX-04 Vaccine At American Society Of Hematology Annual Meeting Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for EVX-04, an…
globenewswire.com Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology…
globenewswire.com Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio…
globenewswire.com Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud…
seekingalpha.com Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
defenseworld.net Evaxion A/S (NASDAQ:EVAX) Shares Break Below 200 Day Moving Average – What’s Next? Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…benzinga.com Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in…
globenewswire.com Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
globenewswire.com Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
globenewswire.com Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will…
defenseworld.net Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX) Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
globenewswire.com Evaxion applies its AI-Immunology™ platform in autoimmune diseases Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique…
seekingalpha.com Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
globenewswire.com Evaxion announces business update and second quarter 2026 financial results COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides…
globenewswire.com Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it…
globenewswire.com Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a…
globenewswire.com Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present…
globenewswire.com Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data…
